Sunday November 8 2009 | Biotechnology feed | All feeds

GlaxoSmithKline

Smithkline Beecham Corporation, Philadelphia PA, United States of America.

GSK Submits TYVERB(R)/TYKERB(R) (lapatinib) for First-Line Treatment of Metastatic Breast Cancer in Europe, US

BioPortfolio no longer holds the full text of this article, it is however likley to be available via the below links:

GSK Submits TYVERB(R)/TYKERB(R) (lapatinib) for First-Line ... 1 Apr 2009 ... GSK Submits TYVERB(R)/TYKERB(R) (lapatinib) for First-Line Treatment of Metastatic Breast Cancer in Europe, US LONDON and PHILADELPHIA, ...
http://www.reuters.com/article/pressRelease/idUS132817+01-Ap...

Browse other news from this organisation: GlaxoSmithKline

(If any, Generated Automatically)

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.